Resistant social anxiety disorder response to Escitalopram

Clinical Practice and Epidemiology in Mental Health

Volumn 2, Issue , 2006, Pages

  Pallanti, Stefano ^a,b,c   Quercioli, Leonardo ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Psichiatria P   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; PAROXETINE;

ADULT; AGITATION; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MALE; NAUSEA; OPEN STUDY; OUTPATIENT; PATIENT COMPLIANCE; SCORING SYSTEM; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT OUTCOME;

EID: 33846707659     PISSN: 17450179     EISSN: None     Source Type: Journal    
DOI: 10.1186/1745-0179-2-35     Document Type: Article

References (24)

1. Ansseau M Reggers J Nickels J Magerus S Epidémiologie des troubles psychiatriques dans la province de Luxembourg, Plate-forme de concertation Psychiatrique, Université de Liège, Belgique
2. Kringlen E Torgersen S Cramer V A Norwegian psychiatric epidemiological study Am J Psychiatry 2001 158 1091-91 10.1176/appi.ajp.158.7.1091 11431231
3. Iancu I Levin J Hermesh H Dannon P Poreh A Ben-Yehuda Y Kaplan Z Marom S Kotler M Social phobia symptoms: Prevalence, sociodemographic correlates, and overlap with specific phobia symptoms Compr Psychiatry 2006 47 5 399-405 10.1016/j.comppsych.2006.01.008 16905404
4. Blanco C Raza MS Schneier FR Liebowitz MR The evidence-based pharmacological treatment of social anxiety disorder Int J Neuropsychopharmacol 2003 6 4 427-42 10.1017/S1461145703003791 14609440
5. Davidson J Yaryura-Tobias J DuPont R Stallings L Barbato LM van der Hoop RG Li D Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder J Clin Psychopharmacol 2004 24 2 118-25 10.1097/01.jcp.0000106222.36344.96 15206657
6. Allgulander C Paroxetine in social anxiety disorder: A randomized placebo-controlled study Acta Psychiatr Scand 1999 100 193-198 10493085
7. Baldwin DS Bobes J Stein DJ Scharwachter I Faure M A randomised, double-blind, placebo-controlled study of paroxetine in the treatment of social phobia/social anxiety disorder Br J Psychiatry 1999 175 120-26 10627793
8. Lydiard RB Bobes J Therapeutic advances: Paroxetine for the treatment of social anxiety disorder Depress Anxiety 2000 11 99-104 10.1002/ (SICI)1520-6394(2000)11:3<99::AID-DA3>3.0.CO;2-Z 10875050
9. Stein MB Chartier MJ Hazen AL Kroft CD Chale RA Cote D Walker JR Paroxetine in the treatment of generalised social phobia: Open-label treatment and double-blind, placebo-controlled discontinuation J Clin Psychopharmacol 1996 16 218-222 10.1097/00004714-199606000-00005 8784653
10. Stein DJ Versiani M Hair T Kumar R Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study Arch Gen Psychiatry 2002 59 12 1111-8 10.1001/archpsyc.59.12.1111 12470127
11. Van Ameringen M Mancini C Pipe B Bennett M Optimizing treatment in social phobia: A review of treatment resistance CNS Spectr 2004 9 10 753-62 15448580
12. Atmaca M Kuloglu M Tezcan E Unal A Efficacy of citalopram and moclobemide in patients with social phobia: Some preliminary findings Hum Psychopharmacol 2002 17 8 401-5 10.1002/hup.436 12457375
13. Varia IM Cloutier CA Doraiswamy PM Treatment of social anxiety disorder with citalopram Prog Neuropsychopharmacol Biol Psychiatry 2002 26 1 205-8 10.1016/S0278-5846(01)00236-6 11853114
14. Simon NM Korbly NB Worthington JJ Kinrys G Pollack MH Citalopram for Social Anxiety Disorder: An Open-label Pilot Study in Refractory and Nonrefractory Patients CNS Spectr 2002 7 9 655-7 15097929
15. Shlik J Maron E Tru I Aluoja A Vasar V Citalopram challenge in social anxiety disorder Int J Neuropsychopharmacol 2004 7 2 177-82 10.1017/ S146114570300405X 14741063
16. Sanchez C Gruca P Bien E Papp M R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety Pharmacol Biochem Behav 2003 75 4 903-7 10.1016/S0091-3057(03)00165-5 12957234
17. El Khoury A Gruber SH Mork A Mathe AA Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression Prog Neuropsychopharmacol Biol Psychiatry 2006 30 3 535-40 10.1016/j.pnpbp.2005.11.011 16414167
18. Lepola UM Loft H Reines EH Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care Int Clin Psychopharmacol 2003 18 4 211-7 10.1097/ 00004850-200307000-00003 12817155
19. Wade A Friis Andersen H The onset of effect for escitalopram and its relevance for the clinical management of depression Curr Med Res Opin 2006 22 11 2101-10 10.1185/030079906X148319 17076970
20. Lader M Stender K Burger V Nil R Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study Depress Anxiety 2004 19 4 241-8 10.1002/da.20014 15274173
21. Kasper S Stein DJ Loft H Nil R Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study Br J Psychiatry 2005 186 222-6 10.1192/bjp.186.3.222 15738503
22. Goodman WK Bose A Wang Q Treatment of generalized anxiety disorder with escitalopram: Pooled results from double-blind, placebo-controlled trials J Affect Disord 2005 87 2-3 161-7 10.1016/j.jad.2004.11.011 15982747
23. Stein DJ Andersen EW Lader M Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes Ann Clin Psychiatry 2005 17 2 71-5 10.1080/10401230590932335 16075659
24. Spadone C Effects of escitalopram on anxiety symptoms in depression Encephale 2002 28 5 Pt 1 461-5 12386549